PUBLIC COMPANY
save$NUVBNuvation Bio Inc.
$NUVB6.2200+1.97%New York, NY, USupdated 8h ago
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 31Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
- phase1Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib
- phase3SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- phase3Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- phase3A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- phase2A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
- phase2Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
- phase2Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 17, 26option exerciseWentworth Kerry · CHIEF REGULATORY OFFICER36,750 sh
- Apr 17, 26option exerciseLiu Dongfang · CHIEF MEDICAL OFFICER50,000 sh
- Apr 17, 26option exerciseLiu Dongfang · CHIEF MEDICAL OFFICER50,000 sh
- Apr 17, 26option exerciseWentworth Kerry · CHIEF REGULATORY OFFICER36,750 sh
- Apr 6, 26option exerciseWentworth Kerry · CHIEF REGULATORY OFFICER100,000 sh
- Apr 6, 26option exerciseWentworth Kerry · CHIEF REGULATORY OFFICER100,000 sh
🐶 Hiring Signal
next earnings Nov 2, 2026
News
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that